Neovacs announces that it has been granted a new patent from the Russian Federation Patent Office titled Method of treatment of a disease related to the over expression of IFNalpha. This patent significantly strengthens Neovacs' Interferon alpha (IFNalpha)-related intellectual property portfolio, protecting the Company's core technology platform, product candidates and applications worldwide until at least 2032.